Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ATI-1428
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-1428 and ATI-1645 are 4th generation, class II capsid assembly modulators (CAMs), both with a novel and unique ultra-potent mechanism of action design that may provide for a more targeted, productive antiviral response by the immune system.
Product Name : ATI-1428
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : ATI-1428
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated with alanine aminotransferase (ALT) normalization and no ALT flares off-treatment.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2022
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Tenofovir,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-2173, once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate, only active site polymerase inhibitor nucleotide for HBV in clinical development.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : ATI-2173,Tenofovir,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data showed that ATI-2173 alone, or in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated among the cohorts, and ATI-2173 and TDF suppressed HBV DNA and induced declines in biomarkers of cccDNA activity.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2022
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The double-blind randomized controlled trial plans to enroll 30 patients and will assess the safety and efficacy of 25mg and 50mg doses of ATI-2173 in combination with tenofovir (TDF) compared with TDF plus ATI-placebo (control) in chronic HBV-infected s...
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2021
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : RA Capital Management
Deal Size : $96.0 million
Deal Type : Series B Financing
Antios Therapeutics Raises $96 Million in a Series B Financing
Details : The proceeds from this financing will support the ongoing Phase 2 clinical program which is evaluating the potential for the Company’s lead clinical candidate, ATI-2173, to be a backbone of a once-daily curative regimen for chronic hepatitis B.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 13, 2021
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : RA Capital Management
Deal Size : $96.0 million
Deal Type : Series B Financing
Lead Product(s) : ATI-2173,AB-729,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : GordonMD Global Investments
Deal Size : $75.0 million
Deal Type : Series B Financing
Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV
Details : The proceeds from this financing will be used to advance the clinical development of ATI-2173, Antios’ lead Phase 2b clinical candidate. ATI-2173 is the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 11, 2021
Lead Product(s) : ATI-2173,AB-729,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : GordonMD Global Investments
Deal Size : $75.0 million
Deal Type : Series B Financing
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The placebo-controlled Phase 1b trial evaluated the safety, tolerability, pharmacokinetics, and measurable reductions in HBV viral load of multiple oral doses of ATI-2173 in 24 patients with chronic HBV infection.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 25, 2021
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Antios Therapeutics Initiates First-in-Human Study of ATI-2173
Details : The Phase Ia study is a randomized, double-blind, placebo-controlled single-ascending dose study in healthy volunteers to evaluate the ATI-2173's safety, tolerability and pharmacokinetic profile.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2020
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Antios Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering ATI-2173
Details : The patent covered covering the composition of matter and methods of use for ATI-2173.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2020
Lead Product(s) : ATI-2173
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable